ISSN Updates HMB Position Stand With 12 Evidence-Based Recommendations
The International Society of Sports Nutrition's comprehensive 2025 review affirms HMB's safety and multi-faceted benefits for muscle, performance, and aging.
Summary
The ISSN's updated position stand on β-hydroxy-β-methylbutyrate (HMB) synthesizes nearly three decades of research into 12 consensus points. HMB, a leucine metabolite naturally produced in humans, exists in two supplemental forms: calcium HMB (HMB-Ca) and free acid HMB (HMB-FA). Both are confirmed safe for up to one year of use, with no adverse effects on renal, hepatic, or hematological markers. HMB works primarily by stimulating muscle protein synthesis via mTORC1 (independent of the leucine-sensing Sestrin2-GATOR2 pathway) while simultaneously suppressing muscle protein breakdown. Benefits span improved body composition, strength, recovery, and aerobic performance across untrained and trained individuals, older adults, and those experiencing muscle disuse atrophy.
Detailed Summary
**Why This Matters** HMB has been commercially available and scientifically studied for nearly 30 years, yet confusion persists about its mechanisms, optimal use, and who benefits most. This updated ISSN position stand — replacing the original published over a decade ago — synthesizes a database of over 750 articles to provide clear, evidence-based guidance for athletes, clinicians, and aging populations alike.
**What Was Studied** Authors conducted a comprehensive scoping review using PubMed, Google Scholar, and ResearchGate, focusing on HMB's forms and bioavailability, safety/toxicity, mechanisms of action, effects on body composition, strength, power, aerobic performance, aging and sarcopenia, disuse atrophy, and nutrient interactions. The standard supplemental dose studied is 38 mg/kg body weight per day (typically ~3 g/day for a 70-kg adult), with studies ranging from 1.5 to 6 g/day.
**Key Results** HMB-FA achieves higher and earlier plasma peaks than HMB-Ca in most (though not all) kinetic studies, suggesting superior bioavailability in most formulations. Both forms demonstrate an excellent long-term safety profile — rat NOAEL data extrapolate to >30 g/day in humans, over 10 times the recommended dose, and year-long human studies report no adverse clinical or laboratory findings. HMB improves body composition (increased lean mass, decreased fat mass) most robustly when combined with structured resistance training and dietary control. Strength and power gains are clearer in untrained individuals, while performance benefits in trained athletes become more apparent in studies exceeding six weeks, likely driven by enhanced recovery. Notably, HMB activates mTORC1 independently of the classical leucine-sensing pathway, suggesting it can stimulate muscle protein synthesis even when leucine signaling is saturated. For older adults, HMB improves muscle strength and quality in sedentary populations, and may help counter sarcopenia and disuse atrophy — including via modulation of mitochondrial dynamics and lipid metabolism.
**Implications** HMB's dual mechanism — promoting anabolism and suppressing catabolism — makes it relevant not just for athletes but for clinical populations facing muscle wasting (cancer cachexia, HIV-associated weight loss, immobilization, aging). Its potential to improve glucose metabolism in younger adults and modest cardiovascular benefits (reductions in LDL cholesterol and systolic blood pressure) add further clinical value. Timing HMB intake close to exercise may maximize benefits for muscle protein synthesis and inflammation attenuation.
**Caveats** Results in trained athletes remain mixed, particularly for shorter study durations. Bioavailability comparisons between HMB-Ca and HMB-FA are complicated by formulation differences across studies. Most combination nutrient studies (HMB + arginine, lysine, vitamin D) make it difficult to isolate HMB's independent contribution.
Key Findings
- HMB is safe for chronic human use up to one year, with NOAEL extrapolating to >30 g/day — 10× the recommended dose.
- HMB activates mTORC1 independently of the leucine-sensing Sestrin2-GATOR2 pathway, enabling anabolic signaling via a distinct mechanism.
- Daily HMB (38 mg/kg) combined with resistance training improves lean mass and reduces fat mass across ages, sexes, and training levels.
- HMB may counter disuse muscle atrophy through modulation of mitochondrial dynamics and lipid metabolism, beyond protein turnover effects.
- Performance benefits in trained athletes require study durations >6 weeks and are likely mediated through improved recovery rather than direct anabolic effects.
Methodology
This is an ISSN position stand based on a scoping review of over 750 original articles and reviews identified via PubMed, Google Scholar, and ResearchGate. The consensus document was drafted by a multidisciplinary expert author group, reviewed by leading scholars, and approved by the ISSN Research Committee. It is not a formal systematic review or meta-analysis.
Study Limitations
Evidence in highly trained athletes is inconsistent, and many studies are short-duration (<6 weeks), limiting conclusions about long-term performance effects. Several multi-ingredient combination studies make it difficult to attribute observed benefits solely to HMB. Bioavailability data comparing HMB-Ca and HMB-FA are complicated by differing capsule formulations across studies, introducing methodological inconsistency.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.